Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing TSA
Not Applicable
Completed
- Conditions
- Osteoarthritis: Shoulder
- Interventions
- Procedure: Interscalene brachial plexus blockProcedure: bupivacaine extended-release liposome injection
- Registration Number
- NCT02695758
- Lead Sponsor
- Rothman Institute Orthopaedics
- Brief Summary
A non-blinded randomized controlled trial, in which participants undergoing primary reverse or total shoulder arthroplasty are randomly assigned to one of two treatment groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
- All individuals undergoing primary reverse and total shoulder arthroplasty by the shoulder service at Methodist Hospital or Rothman Specialty Hospital.
Exclusion Criteria
- Psychiatric illness as defined by co-morbid diagnosis of bipolar disorder or schizophrenia
- Revision arthroplasty, arthroplasty for fracture
- Unable/unwilling to consent for enrollment
- Unable to complete postoperative pain survey
- Known adverse drug reaction or allergy to the medications used
- Chronic pain syndromes (including reflex sympathetic dystrophy, fibromyalgia, chronic diffuse musculoskeletal pain)
- Patients taking long acting narcotic pain medications (including extended release narcotic pain medications and methadone).
- Patients under the age of 18 years
- Patients with history of hepatic disease
- Pregnant women or women who are breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description interscalene brachial plexus block Interscalene brachial plexus block Direct interscalene nerve block injection via brachial plexus Bupivacaine extended-release liposome injection bupivacaine extended-release liposome injection Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
- Primary Outcome Measures
Name Time Method Morphine and Morphine Equivalent consumption 24 hours following surgery
- Secondary Outcome Measures
Name Time Method